Abstract: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.

Abstract: Provided is a novel conjugate of a primary or secondary amine compound with an acidic polysaccharide, which is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, where in Formula (I), D, R1, R2, A, and Poly are as defined in the specification.

Abstract: A horseshoe crab Factor C protein having activity of Factor C, wherein the horseshoe crab is selected from Tachypleus tridentatus, Limulus polyphemus, and Carcinoscorpius rotundicauda, and wherein the horseshoe crab Factor C protein is produced through being recombinantly expressed from a Chinese Hamster Ovary (CHO) DG44 cell or HEK cell.

Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.

Abstract: Provided is a method for suppressing the generation of diclofenac lactam from a compound represented by a formula (1) in the description, including allowing the compound of the formula (1) and a component (A) that is at least one type of compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1 to C3 mono-alcohol, a C2 to C3 di-alcohol, a C3 to C6 tri-alcohol, a polyalkylene glycol, a ?-lactone, polyvinylpyrrolidone, a chlorogenic acid, and an alkyl sulfate ester, and salts thereof to coexist. A method for producing a pharmaceutical composition containing a compound represented by the formula (1) and a component (A), and a pharmaceutical composition which is a product produced thereby are also provided.

Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

Abstract: Provided is an agent for proving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.

Abstract: Provided is a technology related to a horseshoe crab factor B variant, and also provided is means for performing endotoxin measurement with high sensitivity. A polypeptide having an amino acid sequence in which the amino acid residue at the 193-position in an amino acid sequence of a polypeptide of horseshoe crab factor B is substituted with a cysteine (Cys) residue, is produced. Endotoxin measurement can be carried out with high sensitivity by configuring a Limulus reagent by combining this polypeptide with horseshoe crab factor C.

Abstract: A method for rapidly and highly sensitively measuring endotoxin relies on an endotoxin-measuring agent, which includes a factor C derived from Tachypleus tridentatus that does not have His-tag sequence at the C-terminus, a factor B of a horseshoe crab, and a proclotting enzyme of a horseshoe crab. Each of these proteins can be a recombinant protein obtainable by being expressed using a stably expressing cell line of an insect cell as a host.

Abstract: Provided is an agent for proving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.

Abstract: An object of the present invention is to provide a method for enhancing a sensitivity of a current endotoxin measuring reagent employing a recombinant protein to the endotoxin of Helicobacter pylori. The present invention provides a method for enhancing the sensitivity of an endotoxin measuring reagent to the endotoxin of Helicobacter pylori, the endotoxin measuring reagent containing a recombinant protein of horseshoe crab factor C, the method including increasing a content of the recombinant protein of factor C at the time of endotoxin measurement to an amount that is sufficient for enhancing the sensitivity.

Abstract: To provide a method for producing a horseshoe crab recombinant Factor C. The horseshoe crab recombinant Factor C is produced through expression thereof by use of mammalian cells such as CHO DG44 and HEK293 as host cells.

Abstract: An object of the present invention is to provide means for correctly measuring zygomycota. The present inventors have found that conventionally difficult zygomycota measurement can be performed through subjecting an untreated specimen to an acid treatment. The present invention provides a method for measuring zygomycota, the method including measuring zygomycota in a specimen that was subjected to an acid treatment; an agent for preparing a specimen for measurement of zygomycota; a method for preparing a specimen for measurement of zygomycota; and a reagent kit for measuring zygomycota.

Abstract: A compound includes a group derived from chondroitin sulfate, a group derived from a steroid, and a spacer. The group derived from the chondroitin sulfate and the group derived from the steroid are covalently bonded together via the spacer, and a spacer forming molecule of the spacer is ?-alanine or isoleucine. A covalent bond between the group derived from the steroid and the spacer is an ester bond, and a covalent bond between the group derived from the chondroitin sulfate and the spacer is an amide bond. The steroid is at least one selected from the group consisting of prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide and fluticasone.

Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.

Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

Abstract: The present application provides: a technique for promoting hyaluronic acid synthesis by hyaluronic acid-producing cells; a method for evaluating the responsiveness of hyaluronic acid-producing cells to a compound; or a method for evaluating the responsiveness of a polysaccharide derivative represented by formula 1 in the description or a salt thereof to hyaluronic acid-producing cells. By bringing a polysaccharide derivative represented by formula 1 in the description or a salt thereof into contact with hyaluronic acid-producing cells, promotion of hyaluronic acid synthesis is achieved in the hyaluronic acid-producing cells. Further, by using the polysaccharide derivative or a salt thereof for hyaluronic acid-producing cells, the responsiveness of the hyaluronic acid-producing cells can be evaluated using the production of hyaluronic acid as an index.

Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. Specifically provided is a composition for treating joint diseases that obtains higher efficacy than prior preparations by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is targeted at patients with human joint diseases who have a BMI of 25 kg/m2 or higher.

Abstract: The invention provides a diamine crosslinking agent for acidic polysaccharides consisting of a diamine compound having a primary amino group at both terminals and an ester or thioester bond in the molecule, wherein the number of atom in the linear chain between at least one of the amino groups and the carbonyl carbon in the ester or thioester is 1 to 5; in particular, a diamine crosslinking agent for acidic polysaccharides which is represented by the general formula (I) below: [the symbols in the formula are as described in the specification]; a crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between the amino groups in the diamine crosslinking agent and carboxyl groups in an acidic polysaccharide; and a medical material including the crosslinked product.

Abstract: Provided are a novel conjugate of a bioactive carboxylic acid type compound with a polymer having a carboxy group, represented by Formula (I) as defined in the specification, capable of finely controlling a sustained release rate, and capable of sustainably releasing even a drug in which the vicinity of a carbonyl group of the bioactive carboxylic acid type compound is sterically crowded, and a method for manufacturing the same.